The trajectory of companies tied to iconic drugs like Viagra presents a challenging investment picture. While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial wealth , the loss of exclusivity in key regions has introduced significant volatility. Investors are now facing the consequences of lower-cost